NCT06604351View on ClinicalTrials.gov

Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

May 31, 2029

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Sintilimab, Nab-Paclitaxel, and Carboplatin

Cryoablation received at least 2 or more depending on the mass, with 2-3 cycles；Sintilimab 200 mg Q3W plus Nab-Paclitaxel 260mg / m2(Day 1) Q3W + carboplatin AUC 4.25 or 5 (Day 1) Q3W, 4 cycles，until 24 months

Trial Locations (1)

Unknown

Hunan Cancer hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT06604351 - Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction | Biotech Hunter | Biotech Hunter